A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants

  title={A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants},
  author={Courtney De Vries and Svetla Gadzhanova and Matthew J. Sykes and Michael Ward and Elizabeth Ellen Roughead},
  journal={Drug Safety},
  pages={291 - 312}
Antidepressant use during the first trimester is reported in 4–8% of pregnancies. The use of some selective serotonin reuptake inhibitors during the first trimester has been identified as increasing the odds for congenital heart defects; however, little is known about the safety of non-selective serotonin reuptake inhibitor antidepressants. The objective of this study was to assess the odds of congenital heart defects associated with the use of antidepressants during the first trimester of… 
Assessment of evidence on reported non-genetic risk factors of congenital heart defects: the updated umbrella review
This umbrella review aimed to comprehensively summarize the evidence and grade the evidence of the associations between non-genetic risk factors and CHD and will provide evidence-based information for women of childbearing age before or during pregnancy to prevent CHD.
Antidepressants are not safe during pregnancy and in women of child‐bearing age
The United States Birth Defects Prevention Study confirmed the association between SSRIs and birth defects and that the observational evidence for the benefits of psychotropics during pregnancy is weak.
Beyond the ‘normal’ worries: detection and treatment of perinatal anxiety and anxiety disorders
  • L. Lorenzo
  • Psychology, Medicine
    BJPsych Advances
  • 2022
Key points in the differential diagnosis of perinatal anxiety and its impact on both the pregnancy and the baby are reviewed, as well as aspects of detection and diagnosis.


Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence.
Overall, antidepressants do not appear to be associated with an increased risk of congenital malformations, but statistical significance was found for cardiovascularmalformations.
Fluoxetine and congenital malformations: a systematic review and meta‐analysis of cohort studies
The results of this meta-analysis indicate maternal fluoxetine use is associated with a slightly increased risk of cardiovascular malformations in infants, and health care providers and pregnant women must weigh the risk-benefit potential of these drugs when making decisions about whether to treat with fluoxettine during pregnancy.
Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations
Fluxetine and paroxetine should be avoided in the first trimester and among those at risk of an unplanned pregnancy and the teratogenic effect of individual SSRIs has not been compared using meta-analysis.
The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.
Although the estimates varied depending on the comparator group, study design and malformation detection period, a trend towards increased risk was observed, and the increase in risk is not dependent on the study method or population.
The fetal safety of fluoxetine: a systematic review and meta-analysis.
Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta‐analysis of cohort studies
This meta‐analysis suggested that the use of sertraline use by pregnant women in the first trimester had an increased risk of cardiovascular‐related malformations as well as atrial and/or ventricular septal defects in infants.
Antidepressant use in pregnancy and the risk of cardiac defects.
The results of this large, population-based cohort study suggested no substantial increase in the risk of cardiac malformations attributable to antidepressant use during the first trimester.
Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.
This study suggests a possible association between cardiovascular anomalies and first-trimester exposure to fluoxetine in mothers using selective serotonin reuptake inhibitors.
Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study
Risks of congenital malformations of the heart were similar for pregnancies exposed to an SSRI throughout the first trimester and for pregnancies with paused SSRI treatment during pregnancy, and the authors found no association with dosage.